PPHM:
Analysis & Opinions
-
February 14, 2013
Peregrine Pharmaceuticals (PPHM) recently announced phase II data on its oncology candidate, bavituximab. The ...
-
February 12, 2013
Recently, Celgene Corporation (CELG) announced that the US Food and Drug Administration (FDA) will review the ...
-
February 11, 2013
Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM ...
-
February 07, 2013
Protalix BioTherapeutics, Inc. (PLX) recently confirmed that it has hired Citigroup, Inc. C) to explore strategic ...
-
February 07, 2013
Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical ...
-
February 07, 2013
Medivation, Inc. (MDVN) recently announced that its partner Astellas Pharma Inc. (ALPMY) reported Xtandi ...
-
February 07, 2013
Vivus Inc. (VVUS) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. ...
-
February 05, 2013
Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option ...
-
February 04, 2013
Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris ...
-
January 16, 2013
Alnylam Pharmaceuticals Inc. (ALNY) provided pricing and other details regarding its recently announced public ...
-
January 15, 2013
Alnylam Pharmaceuticals Inc. (ALNY) recently began an underwritten public offering of shares of its common stock. ...
-
January 10, 2013
Geron Corporation (GERN) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. (BTX) and ...
-
January 09, 2013
Regeneron Pharmaceuticals Inc. (REGN) recently announced that sales of its eye drug Eylea for the final quarter of ...
